Creating patient-specific replacement organs promises to address shortcomings in transplantation, including the need for immunosuppression and limited donor supply. A major roadblock to tissue engineering is the inability to synthesize an intact circulatory system de novo. Thus, tissues produced by the current paradigm of seeding cellular scaffolds are rendered critically ischemic by their reliance on diffusion and eventual vascular ingrowth from the implantation site. Here, we describe a novel approach to fabricate vascularized neo-livers by repurposing the body's own expendable microcirculatory beds (EMBs). The use of intact fully patterned circulatory beds, which are used clinically in free tissue transfer, allows immediate perfusion of the neo-livers after vascular anastomosis.
METHODS:
Adipose derived stem cells (ASCs) were exposed to hepatic differentiation media. Hepatic differentiation was assessed by morphology, immunofluorescence, and western blot. In auto-assembly experiments ASCs, endothelial cells (ECs), and hepatocytes were co-cultured and assessed by bright field microscopy and immunofluorescence. Superficial inferior epigastric (SIE) flaps from male Wistar rats (n=3) were raised, detached at the vascular pedicle, and seeded with hepatocytes, ASCs, and ECs ex vivo. Following a two-hour dwell period, the constructs were re-implanted with vascular anastomoses to the femoral vessels. Subsequent neo-liver formation was assessed through a variety of modalities including histology and immunofluorescence.
RESULTS: ASCs exposed to differentiation media demonstrated a distinct morphology change, developing a hepatocyte-like appearance by day 21. Albumin and cytochrome P450 production was confirmed by immunofluorescence and western blot. Co-culture of hepatocytes, ASCs, and ECs recapitulates key developmental cues resulting in functional hepatic bud formation in vitro when assessed by morphology and immunofluorescence. EMBs seeded through intra-vascular perfusion of hepatocytes, ASCs, and ECs form vascularized neo-liver in vivo with sinusoidal architecture and function resembling native liver. These neo-livers express albumin, cytochrome P450, alpha-1-antitrypsin, and other hepatocyte-specific markers.
CONCLUSION:
ASCs can be differentiated into hepatocyte-like cells, ensuring a renewable supply of autologous liver replacement cells. Co-seeding recapitulates the hepatic developmental environment and facilitates auto-assembly of functional liver tissue. Repurposing and seeding the body's own microcirculatory beds with liver-forming cell combinations allows large, functional, vascularized neoliver constructs to be implanted. This represents a major advancement in tissue engineering and paves the way for autologous organ replacement therapy.
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volumes to correct large defects. To address this clinical challenge, we aimed to create an "off-the-shelf " adipose material using mechanical and chemical processing techniques which remove lipids and living cells while processing the tissue into an injectable form preferred by patients and physicians. Preclinical testing of this Acellular Adipose Tissue (AAT) conducted in mouse, rat, and swine models demonstrated the biocompatibility of the AAT implants and their ability to provide soft tissue volume replacement while promoting the migration of adipose stem cells (ASCs) into the tissue matrix. The aim of our present study is to assess the safety of AAT in healthy human volunteers.
METHODS:
A 12-week, prospective, Phase I study in healthy volunteers assessing the safety and tolerability of AAT intended for the repair of soft tissue defects in humans was initiated. The trial evaluated subcutaneous injections of AAT administered in redundant tissues previously scheduled for surgical removal in an elective surgical procedure (i.e., panniculectomy). Participants enrolled in excision time points ranging from 1 to 12 weeks postinjection. Excised implants were assessed using histopathological analyses including hematoxylin and eosin staining (H&E) and by flow cytometry (FACS). The primary outcome of safety was determined by the incidence and rate of adverse and unanticipated events. The secondary outcome of tolerability was determined by patient-and physician-reported satisfaction with the intervention. Histological analysis evaluated cell migration into the matrix and tissue development, two key components of long-term efficacy.
RESULTS: Eight healthy volunteers participated in this
Phase I study assessing the safety of AAT. No patients experienced an adverse or unanticipated event related to their participation in this study. AAT implants were well-tolerated and demonstrated satisfactory participant comfort and physician ease-of-use ratings. Additionally, we evaluated immune profiles of AAT using flow cytometry to quantify the presence of T cells, B cells, dendritic cells, macrophages, M1-polarized (inflammatory) macrophages, and M2-polarized (wound-healing) macrophages. Our preliminary results indicate that AAT is associated with pro-regenerative immune responses, including M2 macrophage polarization and increased IL-4 expression. Tissue engineering seeks to develop physiologically appropriate tissues to restore, maintain or improve function in clinical contexts, and provide platforms with which to study basic biological processes and screen drug candidates and delivery strategies. The complete realization of these goals will represent a paradigm shift. In medicine, it will reduce the use of patient tissue and the associated morbidity at donor sites; in drug development, it will improve the economics and efficacy of early stage drug screening and replace animal testing with appropriate human tissues. We have pioneered approaches to form microvascular networks within 3-D tissue scaffolds. Despite our successes, the overall field has suffered from the lack of a complete suite of tools with which to control these complex cultures with respect to both physical and biological parameters and make them compatible with microsurgery. Here we present an autonomous tissue cartridge (ATC) for recapitulation of the microvasculature in vitro which solves these problems on three fronts: 1) Precise control of flows within vessels, which can perfuse the microvascular networks with nanoliter-precision control. 2) Hardware that enables fluidic, thermal and gas-phase (O 2 , CO 2 , H 2 O) control of culture parameters in a compact, portable and versatile benchtop platform. Importantly, this platform eliminates the need for conventional incubators and provides live fluorescence imaging during long-term cultures 3) Scaffolding procedures that enable microsurgical anastomosis of an endothelialized vessel within a 3-D matrix in an animal model. Results from the system that study the effect of hemodynamic forces on vascular cells provide new biological insights.
METHODS:
Microvessel tissue templates were constructed in Type I collagen using soft lithography and seeded with human umbilical vein endothelial cells. The fully assembled microfluidic tissue culture device with enclosed microvessels was cultured in the benchtop system with live imaging for 3-7 days under pump-driven flow using a range of flow rates to achieve physiologic shear stress against the vessel
